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Background: This study describes initial testing and evaluation of a vertical-field open Magnetic Resonance Imaging
(MRI) scanner for the purpose of simulation in radiation therapy for prostate cancer. We have evaluated the clinical
workflow of using open MRI as a sole modality for simulation and planning. Relevant results related to MRI alignment
(vs. CT) reference dataset with Cone-Beam CT (CBCT) for daily localization are presented.
Methods: Ten patients participated in an IRB approved study utilizing MRI along with CT simulation with the intent of
evaluating the MRI-simulation process. Differences in prostate gland volume, seminal vesicles, and penile bulb were
assessed with MRI and compared to CT. To evaluate dose calculation accuracy, bulk-density-assignments were mapped
onto respective MRI datasets and treated IMRT plans were re-calculated. For image localization purposes, 400 CBCTs
were re-evaluated with MRI as the reference dataset and daily shifts compared against CBCT-to-CT registration. Planning
margins based on MRI/CBCT shifts were computed using the van Herk formalism.
Results: Significant organ contour differences were noted between MRI and CT. Prostate volumes were on average
39.7% (p = 0.002) larger on CT than MRI. No significant difference was found in seminal vesicle volumes (p = 0.454).
Penile bulb volumes were 61.1% higher on CT, without statistical significance (p = 0.074). MRI-based dose calculations
with assigned bulk densities produced agreement within 1% with heterogeneity corrected CT calculations. The differences
in shift positions for the cohort between CBCT-to-CT registration and CBCT-to-MRI registration are −0.15 ±
0.25 cm (anterior-posterior), 0.05 ± 0.19 cm (superior-inferior), and −0.01 ± 0.14 cm (left-right).
Conclusions: This study confirms the potential of using an open-field MRI scanner as primary imaging modality for
prostate cancer treatment planning simulation, dose calculations and daily image localization.
Keywords: MRI simulation, CBCT localization, MRI dose calculation, Anatomical delineation, Radiation OncologyBackground
Magnetic resonance imaging (MRI) is a supplement to
computed tomography (CT) in radiation oncology where
superior soft tissue contrast is required for anatomical
delineation. MRI simulation in radiation therapy (RT)
could potentially be a routine modality in the future pri-
marily because MRI offers the ability to image tumors
and surrounding healthy tissues with significantly better
soft tissue contrast than CT (lung being a notable exception).* Correspondence: adoemer1@hfhs.org
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unless otherwise stated.MRI is an established standard for target and organ-at-risk
delineation for brain and spinal cord cancers and is used in
conjunction with CT for treatment planning [1-3]. In pros-
tate treatment in particular, MRI as a visualization tool for
structures has been investigated [4-7].
MRI-only workflows have been introduced with the
primary endpoint of eliminating the need for CT simula-
tion (CT-SIM). Devic [8] provides an excellent review of
the current use of MRI in radiation oncology, including
MRI simulation. Recently, MRI-only simulators have been
introduced, incorporating features commonly found in
CT-SIM: flat table tops to accommodate immobilization
devices and external laser systems for patient marking andl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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agreement in patient positioning between MRI and radi-
ation therapy delivery. As MRI technology continues to
evolve, new radiation therapy systems are utilizing MRI as
an on-board localization technology, such as the three co-
balt source unit from ViewRay (Oakwood Village, OH)
[9], the MRI-LINAC from Elekta (Stockholm, SE) [10], or
the MRI-on-rails solution being installed at Princess
Margaret Hospital in Toronto, CA [11].
Nevertheless, CT-SIM remains the gold standard for
treatment planning because CT voxels demonstrate a tis-
sue’s electron density, a factor critical to determining the
absorbed dose, as well excellent geometric accuracy and
less stringent safety considerations. Electron density in-
formation is not easily accessible from MRI; and in an
MRI-only simulation workflow treatment planners need
to assign bulk densities to multiple contours that are not
currently generated in a CT workflow. MRI treatment
planning is currently a topic of considerable interest in
radiation oncology [12-15]. Despite its promise, issues
related to geometric distortions (stemming from mag-
netic field inhomogeneities [16,17] and patient-induced
artifacts [18,19]), dose calculation [20-22] and the use of
MRI datasets for image-guidance need to be optimized
to facilitate accurate and efficient clinical workflow.
This study’s goal was to evaluate the potential of
vertical-field open design MRI scanner as a primary
modality for simulation, planning, and IGRT-based
localization for treatment of patients with prostate can-
cers. Dose calculation accuracy was evaluated, includ-
ing the use of bulk density assignments to overcome
limitations in electron density conversion of the MRI
signal. A unique aspect of our study centers on using
MRI as a reference dataset for CBCT-MRI, 3D-3D
image registration for image-guided RT. Such data is
important for routine clinical use of MRI, and has not
been previously published. Additionally, for an open
platform MRI simulator, we investigated issues related
to image acquisition sequences, and the possible pitfalls
of improper imaging and its effect on anatomical contouring.
Methods
Ten prostate cancer patients enrolled on an Institutional
Review Board approved study (to be in compliance of
the Helsinki declaration) had a MRI acquired along with
standard CT simulation. MRIs were obtained from a one
Tesla (1.0 T) open MRI scanner (Panorama, Philips
Healthcare, Best, Netherlands) that has been developed
as a simulation device for RT procedures. Figure 1 shows
our workflow for CT and MRI simulation. Whole pelvis
acquisitions were performed using T1-weighted Fast Field
Echo, T2-weighted Turbo Spin Echo and 3D balanced
Turbo Field Echo (bTFE) sequences. Table 1 shows acqui-
sition parameters for these scans. T1 and T2 scans werefull field of view (FOV) in order to use them for treatment
planning. The bTFE scans were ‘coned-down’ to smaller
regions of interest to help keep acquisition time down and
allow for improved organ delineation. Of note is that these
acquisition parameters are optimized for RT planning by
the manufacturer, and are not applicable to diagnostic
imaging protocols. A flat table top insert (Civco, Orange
City, IA) was used to reproduce typical patient positioning.
The MRI simulation process shares many aspects with
CT simulation. The anatomy of interest (pelvis, head, etc.)
is externally targeted and then moved to the magnet iso-
center. A three plane survey (analogous to CT scouts) is
performed with the largest FOV to determine the acquisi-
tion volume. Acquisition time for three whole pelvis se-
quences totals twenty minutes.
Anatomical contouring
All anatomical delineation and planning were done in
Eclipse® (Varian Medical Systems, Palo Alto, CA). First,
all MRIs were rigidly registered to CT images focusing
on a match of the prostate. Secondly, organ delineation
was performed/reviewed by a single observer for the T1-
MRI and CT images. Retrospectively, another observer
contoured the T2 and bTFE volumes. All contours were
reviewed by an attending physician.
Treatment planning
All patients were planned using intensity modulated ra-
diation therapy (IMRT) with seven or nine fields. The
clinical target volume (CTV) was defined as prostate or
as prostate plus proximal seminal vesicles based on dis-
ease staging. For patient treatment, the prostate volume
was based on the CT volume instead of the MRI drawn
prostate volume. The planned target volume (PTV) was
an expansion of the CTV by 1 cm in all directions ex-
cept 0.6 cm posteriorly. IMRT dose constraints followed
QUANTEC [23] guidelines. Plans were prescribed so the
dose to ninety-five percent of the volume (D95) was
75.6 Gy in 42 fractions.
Retrospective dose calculations were performed on
T1-MRI images using bulk-density-assignment for each
of the structures (body contour, PTV, seminal vesicles,
bladder, rectum, penile bulb and bony structure), by
assigning bony tissue to 480 Hounsfield units (HU) and
soft tissue to 0 HU (water equivalent). The bone value
(480 HU) was determined by contouring bony tissue on
CT and measuring the average CT number. Soft tissue is
comprised of fat and muscle which have HU values
slightly lower and higher than water, respectively, so we
chose to represent all soft tissue with water density. No
air pockets were present in the treated area. Had they
been present, a value of −1000 HU would have been
used. Bulk-density-assignment for dose calculation using
MRI datasets in the context of prostate cancer have been
Figure 1 Study workflow.
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be used to generate dose plans in Eclipse v11. Instead,
unit-density CT datasets were registered to MRI datasets
and MRI contours copied to CT to create workable data-
sets for dose calculation. The same beam angles, leaf
segment positions and monitor units were calculated to
isocenter. We evaluated the impact of bulk-density-
assignment on IMRT optimization using a few represen-
tative datasets. Inverse planning was performed using
bulk-density-assignment and plans were compared to
those in which actual CT densities were used. For both
datasets, the identical beam arrangements, plan and
optimization parameters were used for inverse planning.
The calculated DVHs for the prostate gland, bladder and
rectum were compared.CBCT-based treatment localization
IMRT delivery was performed on Trilogy® and True-
beam® linear accelerators (Varian Medical Systems, Palo
Alto, CA). All patients underwent daily CBCT localization
and shifts were recorded. Retrospectively, another observer
used MRI datasets as the primary reference sets, allowing
for virtual realignment of all CBCT images (~400 datasets).
MRI-CBCT registration was performed manually prioritiz-
ing alignment of the prostate-rectum interface correctly,
which is standard practice. By analyzing these shifts and
using the van Herk formalism [16], we calculated the
CTV-to-PTV margins needed for the CT and MRI refer-
ence sets. This formalism calculates the margins needed
to deliver 95% of the prescribed dose to 90% of the patient
population. It is calculated using the cohort’s inter-patient
Table 1 MRI acquisition parameters
T2 TSE T1 FFE bTFE
Weighting T2 T1 T2/T1
Acquisition 2D 3D 3D
Scan duration (min:sec) 07:13.5 07:38.8 06:18.9
TR (ms) 4563 17 5.4
TE (ms) 80 6.9 2.7
ACQ voxel (mm) 1.00/1.00/2.50 1.15/1.50/2.50 1.25/1.25/2.50
REC voxel (mm) 0.69/0.69/2.50 0.69/0.69/2.50 0.60/0.60/2.50
FOV AP (mm) 300 300 260
RL (mm) 440 440 200
FH (mm) 225 225 225
Coil selection BodySp-XL BodySp-XL BodySp-XL
Flip angle (deg) 90 25 75
Orientation axial axial axial
Number of Signal Averages (NSA) 1 1 2
Fat Saturation none none SPIR
TSE echo spacing/shot (ms) 8.0 / 200 - -
TFE factor - - 256
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the formula [24].
Margin = 2.5 Σ + 0.7 σ. We also calculated the group’s
mean error (M). The inter-patient uncertainty (Σ) is
calculated by averaging all daily shifts and then taking the
standard deviation of each patient’s average value. The inter-
fraction uncertainty (σ) is calculated by taking the stand-
ard deviation of all daily shifts and then taking the root
mean square (RMS) of each patient’s standard deviation.
Results
Anatomical contouring
Volumetric differences in contours from MRI and CT
datasets are summarized in Table 2. Significant differ-
ences were noted between MRI and CT. Prostate and
penile bulb volumes were on average 39.7% (p = 0.002)
and 61.1% (p = 0.074) larger on CT than on MRI re-
spectively. The prostate volume difference agrees well
with values from Roach et al. [25] Seminal vesicle volumes
were underestimated on the CT scan by 1.7% (p = 0.454)
compared to the volumes from MRI. CTV (prostate plus
seminal vesicles) were on average 27.5% (p = 0.002)
smaller on the MRI than they were on CT.
Treatment planning
Inverse-optimized plans using either bulk-density-
assignment or CT-pixel densities have dose parameters
that differ on average by less than 0.5% which was char-
acterized for head and neck IMRT cases by Karotki et al.
[21] We analyzed the dose to 99% and 95% of the
MRI-simulation drawn prostate (D99) and (D95) alongwith the global maximum dose for the MRI- and
CT-based plans. Patient results are presented in Table 3.
Patient eight could not have bulk-density-assignment be-
cause a hip prosthetic did not allow for accurate con-
touring of femoral heads and surrounding bony tissue.
The global maximum dose differed by 1.01% between
MRI and CT plans for the patient cohort, and both the
D99 and D95 were within 0.2% of the CT-based dose
calculation.
CBCT-based treatment localization
Patient 8 was not evaluated for this section due to metal
artifacts impacting CBCT image quality. The averages
and standard deviations of daily shifts used for treatment
localization for each patient are summarized in Table 4.
The differences in shift positions for the entire cohort
between CBCT-to-CT registration and CBCT-to-MRI
registration were −0.15 ± 0.25 cm in the AP direction,
0.07 ± 0.19 cm in the SI direction and −0.01 ± 0.14 cm in
the LR direction.
The margins for the CBCT-CT registration were 0.87 cm
(AP), 0.64 cm (SI) and 0.69 cm (LR) compared to the
CBCT-MRI registration values of 1.06 cm (AP), 0.66 cm
(SI) and 0.68 cm (LR). These margin calculations show that
CBCT-MRI registration is within two millimeters of those
between CBCT-CT. The largest margin difference is in the
AP direction. This is due to bowel preparation issues at
time of MRI simulation. This issue is expanded on in the
discussion section. Imaging modality did not impact daily
localization. MRI performs as well as CT as a reference
image for registration. Figure 2 shows the capability of T1-
Table 2 Anatomical differences between MRI and CT Datasets
Prostate Seminal Vesicles Penile Bulb CTV (prostate + seminal vesicles)
MRI vol (cc) CT vol (cc) MRI vol (cc) CT vol (cc) MRI vol (cc) CT vol (cc) MRI vol (cc) CT vol (cc)
Patient 1 79.46 89.63 16.43 19.96 2.63 3.02 95.89 109.59
Patient 2 83.70 131.00 18.23 7.66 12.98 12.02 101.93 138.66
Patient 3 37.84 56.44 16.22 14.19 3.95 4.45 54.06 70.63
Patient 4 84.20 117.60 11.17 16.47 5.25 8.76 95.37 134.07
Patient 5 26.81 45.14 6.85 9.02 1.95 4.98 33.66 54.16
Patient 6 31.78 50.20 26.59 15.37 4.04 7.15 58.37 65.57
Patient 7 38.94 44.46 22.92 17.27 3.64 4.93 61.86 61.73
Patient 8 30.82 42.13 8.80 5.24 3.44 0.55 39.62 47.37
Patient 9 32.03 42.50 9.44 12.64 2.81 4.74 41.47 55.14
Patient 10 31.76 40.83 14.26 18.02 1.58 5.87 46.02 58.85
%Diff (CT to MRI) 39.7% −1.7% 61.1% 27.5%
St Dev 18.5% 38.1% 96.8% 17.1%
P value 0.002 0.454 0.074 0.002
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by comparing the respective CT/MRI registration to the
same CBCT slice. Some CBCT-MRI registrations were per-
formed multiple times in order to measure the reproduci-
bility, with the registration uncertainty (standard deviation)
being 0.08, 0.09 and 0.07 cm in the AP, SI and LR direc-
tions, respectively.
Discussion
We found clear visual improvement in anatomical delin-
eation from MRI as seen by the agreement of our vol-
ume differences compared to the literature [25]. The
penile bulb is often difficult to discern on CT. The dif-
ference, both spatial and volumetric, between the MRI
volume and the CT volume are stark. Consequently, ifTable 3 Dose differences between CT-based dose calculation
Plan Max Dose D9
MRI (Gy) CT (Gy) MR
Patient 1 76.61 76.97 72
Patient 2 82.43 79.58 77
Patient 3 76.17 74.01 70
Patient 4 74.81 75.17 70
Patient 5 74.25 75.13 70
Patient 6 78.02 77.05 73
Patient 7 78.78 77.46 73
Patient 9 81.59 79.62 76
Patient 10 74.97 75.25 70
Avg Dose Diff. −1.01% −0
STDEV 1.69% −0
P value 0.104 0.8using only CT, we would not be able to offer reduction
of the collateral radiation damage to these structures
during radiation planning and delivery, which may alter
the quality of life of patients treated with radiation.
A novel aspect of our study was using MRI as the ref-
erence dataset for 3D-3D CBCT-MRI matching for
image-guided RT. Such data has not been previously re-
ported for the prostate. Since patients underwent CT
and MRI simulation, we could compare the shifts and
calculated planning margins obtained with the both data-
sets. Looking closely at each patient, differences in shifts be-
tween MRI and CT registration (Table 4) are consistent
overall for each modality. The only registration difference
greater than 3 mm between CT and MRI is for patient 7 in
the AP direction. This is due to non-compliance of boweland MRI bulk density assigned dose calculation
9 for Prostate D95 for Prostate
I (Gy) CT (Gy) MRI (Gy) CT (Gy)
.45 73.70 72.65 73.90
.58 76.05 77.82 76.30
.24 69.78 70.60 70.18
.83 69.10 71.15 70.89
.54 72.01 70.73 72.09
.80 73.76 73.94 73.92
.67 73.42 73.81 73.55
.77 75.77 76.98 75.95




Table 4 Average and standard deviations values for CBCT shifts for all fractions
CT registered to CBCT MRI registered to CBCT
AP (cm) SI (cm) LR (cm) AP (cm) SI (cm) LR (cm)
Patient 1 0.21 ± 0.28 0.04 ± 0.25 0.04 ± 0.29 −0.07 ± 0.25 0.11 ± 0.11 0.03 ± 0.27
Patient 2 0.49 ± 0.30 −0.02 ± 0.54 0.07 ± 0.36 0.44 ± 0.28 0.03 ± 0.54 0.04 ± 0.33
Patient 3 0.04 ± 0.61 0.06 ± 0.53 0.06 ± 0.51 0.01 ± 0.76 0.23 ± .58 0.01 ± 0.48
Patient 4 0.10 ± 0.23 0.18 ± 0.24 −0.08 ± 0.26 0.02 ± 0.15 0.02 ± 0.15 0.00 ± 0.00
Patient 5 0.17 ± 0.32 0.28 ± 0.22 −0.06 ± 0.36 0.27 ± 0.47 0.42 ± 0.27 −0.15 ± 0.38
Patient 6 0.26 ± 0.42 0.02 ± 0.24 0.16 ± 0.19 −0.02 ± 0.33 0.10 ± 0.20 0.10 ± 0.18
Patient 7 −0.06 ± 0.49 −0.18 ± 0.88 0.11 ± 0.64 −0.63 ± 0.49 −0.11 ± 0.86 0.15 ± 0.64
Patient 9 −0.33 ± 0.28 −0.10 ± 0.16 0.30 ± 0.25 −0.28 ± 0.29 −0.02 ± 0.11 0.29 ± 0.27
Patient 10 0.36 ± 0.30 0.05 ± 0.15 −0.32 ± 0.31 0.19 ± 0.29 0.04 ± 0.14 −0.31 ± 0.33
M 0.14 0.04 0.03 −0.01 0.09 0.02
Σ 0.24 0.14 0.17 0.31 0.15 0.17
σ 0.38 0.43 0.38 0.41 0.41 0.36
Margin 0.87 0.64 0.69 1.06 0.66 0.68
Margin† 0.85 0.53 0.67 0.84 0.57 0.64
M is the mean group error, Σ is the inter-patient uncertainty and σ is the inter-fraction uncertainty. The sigma values are used to calculate the needed CTV-PTV
margin using the van Herk formalism.
† Margin not including patient 7, see discussion section.
Doemer et al. Radiation Oncology  (2015) 10:37 Page 6 of 9preparation at the MRI and CT simulations. Due to non-
compliance, the prostate position relative to bony anatomy
changed significantly. Consequently this dramatically im-
pacts registering the CT and MRI images, particularly in
the AP direction, which resulted in systematic differences
(>6 mm) between MRI and CT-generated shifts. If we ex-
clude this outlier data from the analysis, the margins are
nearly identical between MR and CT, as observed in Table 4.
A previous 3D-3D CBCT-MRI matching study performed
by Buhl et al. [26] reported on CBCT shifts compared to
reference MRI images of the brain and showed mean and
standard deviation values of 0.8 ± 0.6 mm, 1.5 ± 1.2 mm
and 1.2 ± 1.2 mm differences in the AP, SI and LR direc-
tions, respectively. These compare very well to our patient
cohort mean and standard deviation values of 1.5 ± 2.5 mm
in the AP direction, 0.7 ± 1.9 mm in the SI direction and
−0.1 ± 1.4 mm in the LR direction.
One disadvantage of the study was that we could not
simulate both MRI and CT during the same appointmentFigure 2 Registration overlays of CBCT with either CT (on the left) orsession. Since patients had to return for another image ac-
quisition there were instances where rectal/bladder filling
was inconsistent between sessions. This created a source
of uncertainty during the image registration process since
changes in bladder and rectum filling could deform other
organs such as the seminal vesicles or prostate. In the clin-
ical implementation of a MRI-only workflow, this source of
error would be mitigated.
During our study, we spent a great deal of effort outlining
the femoral heads and pelvic bones. MRI simulation and
treatment planning relies on correctly delineating all struc-
tures since bulk electron densities are assigned. We found
normal T1 and T2 image acquisitions provided substandard
image quality to properly delineate these bones. bTFE ac-
quisition provided adequate image quality at the expense of
additional scan time. Inverting the T1 image grayscale gave
a clearer outline of the edge of the femoral heads and other
bony structures compared to T1 and T2 images. Image
comparisons can be seen in Figure 3. Future utilization ofMRI (on the right).
Figure 3 Different imaging sequences comparing bone boundaries. Detailed Legend: Imaging sequence from top left going clockwise. CT,
bTFE, Inverted T1, T1. Notice that boundary of the femoral heads and other bony tissue shows up as a region of no signal in the bTFE and T1
image. On the CT and the inverted T1 image, this edge is readily identifiable.
Doemer et al. Radiation Oncology  (2015) 10:37 Page 7 of 9ultra-fast (UTE) [22] and water/fat separating multi-
echo (mDIXON) [27] sequences are likely necessary
for proper identification of bony anatomy. Image registra-
tion to the daily CBCT was found to be straightforward
and uncomplicated. Aligning the capsule edge, seminal
vesicles, rectum interface and the femoral heads was no
more difficult than with a CT reference image.
MRI simulation is not without limitations. The first
consideration with MRI simulation is whether to use
open or closed bore systems. Closed bore systems allow
for greater magnet strength, useful for MRI spectroscopy
and reducing overall scan time. Open-bore systems con-
sist of 2 horizontal magnets. This open design allows for
greater patient comfort and allows simulation therapists
increased access to patients, just as in CT simulation.
However, as open-bore systems tend to use lower strength
magnets which can adversely impact the signal-to-noise
ratio. Our open-MRI system uses rigid radiofrequency
(RF) coils with integrated solenoid technology and receiver
elements perpendicular to the body’s long axis. These are
mounted to the patient table to improve the signal-to-
noise ratio. Using these coils allows our 1.0 T vertical sys-
tem to maximize image quality. Enders et al. [28] found
out that in a blinded randomized study evaluating vertical
and horizontal field image quality, closed-bore systems
had better image quality, though open-bore systems still
had an average image quality grade of ‘moderate’, which
is acceptable in non-diagnostic environments. The last
consideration in bore style is the need to accommodate
immobilization devices that are increasingly utilized in radi-
ation oncology departments in order to fixate patients and
minimize patient motion during simulation and subsequent
treatment. Open-bore systems are more accommodating to
a wider arrange of immobilization devices.
Magnetic field distortions may cause geometric ab-
errations that can result in inaccurate identification ofthe patient’s skin contour, a crucial component to ra-
diation treatment planning [16,17]. It is important that
geometric distortions of each MRI scanner used for
simulation be characterized so that associated uncer-
tainties across the FOV are understood [29,30]. Geo-
metric distortions are classified as system distortions
or object-related distortions. Geometric distortion is
evaluated at our institution on a daily basis for all
three axes using a vendor provided 2-dimensional geo-
metric distortion phantom with a field of view (FOV)
encompassing imaging sequence (~35 cm x 40 cm).
The difference in center of mass position between the
acquired image and the ideal position map is mea-
sured. Deviations are displayed as isocurves that delin-
eate 2 mm distortion within the primary FOV up to
6 mm of distortion at the FOV edge. The plot is visu-
ally inspected to insure the 2 mm isocurve does not
advance past the peripheral imaging region. Object-
related distortions are another concern and cannot be
evaluated with the use of a phantom. Multiple pro-
posals exist for assessing and minimizing object-
related distortion [18,19,31-33], but the issue remains
uncorrected in clinical settings. Distortions due to tis-
sue susceptibility scale almost linearly with the B0 field
strength, and can be considered to be minimal (<0.5 mm)
at a field strength of 1.0 T [31]. Relative to CT, uncorrected
MRI geometric uncertainties can degrade contouring accur-
acy while the enhanced soft-tissue contrast improves con-
touring precision.
Electron density information will always be necessary
for accurate dose calculation. For this study only two
densities were assigned, but in other areas of the body
where air pockets or other tissue densities exist, this
could be a bottleneck for treatment planning efficiency
without intelligent autosegmentation tools. For MRI-
only simulation, we will need to quickly and accurately
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to create so-called “synthetic CTs”, which are cur-
rently being researched to infer electron density infor-
mation directly from MRI [21,34]. For metallic
implants such as hip prostheses, CT can use scatter
correction algorithms to correct for this presence [35],
whereas MRI is compromised by the metal artifact
and could represent a contraindication for MRI-only
simulation. Additional safety concerns need to be
thoroughly investigated and due diligence performed;
any medical product introduced into a high magnetic field
environment must be properly vetted. Examples include
implanted medical devices and infusion catheters. Our
clinic found it necessary to complete MRI screening forms
with the patients three times prior to simulation in order
to guarantee that incompatible materials do not enter
the magnetic field. Patients that are non-compliant in
this regard cannot currently be simulated in a MRI-only
simulation workflow.
Conclusion
This study confirms that MRI has the potential to be a
primary imaging modality for treatment planning
simulation, dose calculations, and daily image localization.
Readily available radiation oncology directed MR
simulation can increase the population of patients that
take advantage of more precise tumor delineation
given the improved soft tissue contrast with MRI.
Consequently it is possible to develop more accurate
treatment plans, which have the potential to positively
influence patient outcomes. Ultimately this hypothesis
needs to be tested, and in this regard, we are currently
performing a prospective clinical trial to correlate patient
outcomes (toxicities and tumor control) with dose
distributions generated using MRI-defined targets.
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